Lung scarring review reports drug benefits, with comparison details missing
A review of randomized drug trials reports lung-function and mortality benefits in progressive fibrotic interstitial lung diseases. Missing comparison details and effect estimates limit interpretation.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
For people with idiopathic pulmonary fibrosis, the review reports that pirfenidone, nintedanib and IFNγ-1b slowed lung-function decline and reduced mortality. The abstract supplies no comparison-specific estimates or confidence intervals. These claims therefore leave the magnitude and precision of the reported differences unclear and do not provide enough detail to identify a best treatment.
This abstract-based summary lacks follow-up periods, treatment-specific comparators and numerical benefit or harm estimates. These omissions prevent assessment of how large or certain the reported differences were.
Separate outcomes were assessed
The review assessed lung-function tests, walking distance, serious adverse events and deaths. These measure different aspects of treatment outcomes. A reported improvement in a lung test alone would not establish an improvement in survival.
Benefits and harms differed
Within the review's progressive fibrotic interstitial lung disease population, several drugs reportedly improved lung function and reduced mortality in connective tissue disease-associated cases. Nintedanib and cyclophosphamide also had more serious adverse events, requiring separate assessment of harms.
The original publication
Clinical efficacy and safety evaluation of drug therapies for the treatment of progressive fibrotic-interstitial lung diseases (PF-ILDs): a network meta-analysis of randomized controlled trials.
Singh P, Thampi G, Gupta K et al.
Expert Rev Clin Immunol · 2025
- PubMed ID
- 40754799
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.